Journal Article

Immunohistochemical detection of malondialdehyde–DNA adducts in human oral mucosa cells

Yujing Zhang, Shu-Yuan Chen, Taming Hsu and Regina M. Santella

in Carcinogenesis

Volume 23, issue 1, pages 207-211
Published in print January 2002 | ISSN: 0143-3334
Published online January 2002 | e-ISSN: 1460-2180 | DOI: http://dx.doi.org/10.1093/carcin/23.1.207
Immunohistochemical detection of malondialdehyde–DNA adducts in human oral mucosa cells

More Like This

Show all results sharing this subject:

  • Clinical Cytogenetics and Molecular Genetics

GO

Show Summary Details

Preview

Malondialdehyde (MDA) is a major lipid peroxidation product that is mutagenic and tumorigenic. MDA-modified DNA adducts have been detected in animal and human tissues and may be a marker of human cancer risk. An immunohistochemical method, using a previously generated monoclonal antibody specific for MDA–DNA adducts, has been developed for the detection and quantification of DNA damage in human oral mucosa cells. The method was used initially on woodchuck liver cells treated with and without MDA, and then applied to the detection of adducts in oral mucosa cells of smokers and non-smokers. Levels of DNA damage were elevated in 25 smokers (mean relative staining intensity 97 ± 41) compared with 25 age-, race- and sex-matched non-smokers (74 ± 17, P < 0.02). These results demonstrate that MDA–DNA adducts can be measured in single cells of human samples by an immunohistochemical method. This methodology provides a simple way to monitor MDA–DNA damage and should be useful for studies investigating the role of exogenous and endogenous agents in oxidative stress and carcinogenesis.

Keywords: GC/MS, gas chromatography/mass spectroscopy; HPLC, high-performance liquid chromatography; MDA, malondialdehyde

Journal Article.  3173 words.  Illustrated.

Subjects: Clinical Cytogenetics and Molecular Genetics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.